|
|
Substance Name: Acyclovir [USAN:USP]
RN: 59277-89-3
UNII: X4HES1O11F
InChIKey: MKUXAQIIEYXACX-UHFFFAOYSA-N
Note
- A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.
Molecular Formula
- C8-H11-N5-O3
Molecular Weight
- 225.2069
- All
- Classifications
- Links to Resources
- Names & Synonyms
- Registry Numbers
- Structure Descriptors
- Toxicity
- Physical Properties
Classification Codes
Classification Codes
- Anti-Infective Agents
- Antiviral
- Antiviral Agents
- Drug / Therapeutic Agent
- Human Data
- Mutation Data
- Reproductive Effect
Superlist Classification Code
- Overall Carcinogenic Evaluation: Group 3
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Regulatory Agencies (Superlist Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Aciclovir [INN]
- Acyclovir
- Acyclovir [USAN:USP]
MeSH Heading
- Acyclovir
Synonyms
- 2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one
- 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-
- 9-((2-Hydroxyethoxy)methyl)guanine
- Aciclovir
- Aciclovirum
- Aciclovirum [INN-Latin]
- Aciclovirum [Latin]
- Activir
- ACV
- Acycloguanosine
- Acyclovir
- BW-248U
- CCRIS 1953
- DRG-0008
- EINECS 261-685-1
- Hascovir
- HSDB 6511
- NSC 645011
- Sitavig
- UNII-X4HES1O11F
- Vipral
- Virorax
- W-248-U
- Wellcome-248U
- Zovirax
Systematic Names
- 6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-
- 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-
- Aciclovir
- Acyclovir
Superlist Name
- Aciclovir
Mixture Name
- Xerese
Registry Numbers
CAS Registry Number
- 59277-89-3
FDA UNII
- X4HES1O11F
System Generated Number
- 0059277893
Structure Descriptors
InChI
InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)InChIKey
MKUXAQIIEYXACX-UHFFFAOYSA-NSmiles
NC1=Nc2c(ncn2COCCO)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
child | TDLo | oral | 3gm/kg/22W-I (3000mg/kg) | BLOOD: AGRANULOCYTOSIS BLOOD: THROMBOCYTOPENIA | American Journal of Emergency Medicine. Vol. 16, Pg. 396, 1998. |
mammal (species unspecified) | LD50 | intravenous | 400mg/kg (400mg/kg) | Pharmacy International. Vol. 5, Pg. 191, 1984. | |
man | TDLo | intravenous | 134ug/kg/1D-I (0.134mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | Lancet. Vol. 2, Pg. 385, 1985. |
man | TDLo | intravenous | 107mg/kg/4D-I (107mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | American Journal of Kidney Diseases. Vol. 22, Pg. 611, 1993. |
man | TDLo | oral | 486mg/kg/17D- (486mg/kg) | GASTROINTESTINAL: OTHER CHANGES GASTROINTESTINAL: DECREASED MOTILITY OR CONSTIPATION | American Journal of Gastroenterology. Vol. 88, Pg. 2110, 1993. |
mouse | LD50 | intraperitoneal | 724mg/kg (724mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 25, Pg. 815, 1994. | |
mouse | LD50 | intravenous | 1118mg/kg (1118mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985. | |
mouse | LD50 | oral | > 10gm/kg (10000mg/kg) | Nature. Vol. 272, Pg. 583, 1978. | |
mouse | LD50 | subcutaneous | 1118mg/kg (1118mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985. | |
rat | LD50 | intraperitoneal | 860mg/kg (860mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985. | |
rat | LD50 | intravenous | 750mg/kg (750mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 25, Pg. 815, 1994. | |
rat | LD50 | oral | > 20gm/kg (20000mg/kg) | Drugs in Japan Vol. -, Pg. 7, 1990. | |
rat | LD50 | subcutaneous | 620mg/kg (620mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985. | |
women | LDLo | multiple routes | 36mg/kg/2D-I (36mg/kg) | BEHAVIORAL: COMA BRAIN AND COVERINGS: OTHER DEGENERATIVE CHANGES LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | American Journal of Kidney Diseases. Vol. 20, Pg. 647, 1992. |
women | TDLo | intravenous | 101mg/kg/2D-I (101mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | American Journal of Medicine. Vol. 94, Pg. 212, 1993. |
women | TDLo | oral | 12mg/kg/1D-I (12mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ANTIPSYCHOTIC BRAIN AND COVERINGS: MENINGEAL CHANGES | Southern Medical Journal. Vol. 87, Pg. 1227, 1994. |
women | TDLo | oral | 28mg/kg/2D-I (28mg/kg) | LUNGS, THORAX, OR RESPIRATION: SPUTUM BRAIN AND COVERINGS: CHANGES IN SURFACE EEG BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | Southern Medical Journal. Vol. 87, Pg. 1227, 1994. |
women | TDLo | oral | 80mg/kg/4D-I (80mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Annals of Internal Medicine. Vol. 111, Pg. 187, 1989. |
women | TDLo | oral | 100mg/kg/5D-I (100mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" | British Medical Journal. Vol. 289, Pg. 1424, 1984. |
Physical Properties
Physical Property | Value | Units | Temp (deg C) | Source |
---|---|---|---|---|
Melting Point | 255 | deg C | EXP | |
log P (octanol-water) | -1.56E+00 | (none) | EXP | |
Water Solubility | 1620 | mg/L | 22 | EXP |
Vapor Pressure | 7.47E-15 | mm Hg | 25 | EST |
Henry's Law Constant | 3.18E-22 | atm-m3/mole | 25 | EST |
Atmospheric OH Rate Constant | 7.94E-11 | cm3/molecule-sec | 25 | EST |
Physical property data is provided to ChemIDplus by SRC, Inc.